A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, which
include genetically modified mycobacteria, mycobacterial antigens delivered by viral …

Correlates of protection (CoPs) are increasingly important in the development and licensure
of vaccines. Although the study of CoPs was initially directed at identifying a single immune …

The majority of vaccine candidates in clinical development are highly purified proteins and
peptides relying on adjuvants to enhance and/or direct immune responses. Despite the …

The only licensed vaccine against tuberculosis (TB), bacille Calmette–Guérin (BCG),
protects against severe extrapulmonary forms of TB but is virtually ineffective against the …

ABSTRACT Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only licensed
vaccine against tuberculosis (TB), yet its moderate efficacy against pulmonary TB calls for …

Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB), is the current
leading cause of death due to a single infectious organism. Although curable, the broad …

CD4 T cells are critical for protective immunity against Mycobacterium tuberculosis (Mtb), the
cause of tuberculosis (TB). Yet to date, TB vaccine candidates that boost antigen-specific …

The year 2020 was shaped by the COVID-19 pandemic which killed more people than any
other infectious disease in this particular year. At the same time, the development of highly …

Tuberculosis is a global threat to which infants are especially vulnerable. Effective vaccines
are required to protect infants from this devastating disease. VPM1002, a novel recombinant …

Tuberculosis (TB), caused by the intracellular bacterium Mycobacterium tuberculosis (Mtb),
remains a major health threat. A live, attenuated mycobacterium known as Bacille Calmette …